Results from AstraZeneca study presented today at ASCO

2018-06-04 10:00

DiviTum results from a large AstraZeneca study are presented today at the ASCO meeting in Chicago, the largest cancer congress in the world.  The study, including 244 women with metastatic breast cancer demonstrates DiviTum’s ability to provide precise prognosis and evaluation of therapy effect for better patient outcome, from a blood sample.

The results are presented in collaboration with AstraZeneca and globally renowned oncologists from EU, US and Canada. By analyzing a blood sample DiviTum provides key information for upfront identification of therapy resistant patients and enables non-invasive monitoring of response to standard hormonal therapies. The Abstract has already been released in mid-May and now there will be a poster session with more comprehensive data presented.

“Circulating levels of TK1, as measured by the DiviTum assay, have demonstrated to be strongly associated with outcome of patients treated with endocrine therapy in different independent datasets, and early data suggest that changes of this proliferation marker during treatment could further inform of treatment benefit. DiviTum assay may be a useful tool in exploring early efficacy signals of oncology agents in development.”– says Gaia Schiavon, Medical Oncologist, Director Physician, IMED Biotech Unit at AstraZeneca.

We look forward to present the results at ASCO showing that DiviTum is able to evaluate treatment efficacy for patients with metastatic breast cancer, treated with endocrine standard treatments. The large number of patients included in the trial also contributes to the strength of the results. We appreciate collaborations with leading pharma companies, like the one with AstraZeneca, and supporting the development of new and improved cancer treatments for better patient outcome.” says Anders Rylander, CEO Biovica.

Malorni L et al, ASCO Annual Meeting 2018; abstract #12031


Numbers of patients in studies




Pharma Projects

Are you a US resident?

Only US residents will be able to qualify for this program